MacroGenics, Inc. (NASDAQ:MGNX) Q4 2024 Earnings Call Transcript
Operator: Good afternoon. We will begin the MacroGenics Fourth Quarter and Full Year 2024 Corporate Progress and Financial Results Conference Call in just a moment.
Macrogenics Inc (MGNX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Armistice Capital Steven Boyd | 6,296,000 | $7,995,920 | +1% | 0.12% |
| 2. | Millennium Management Israel Englander | 1,724,250 | $2,189,798 | -40% | 0% |
| 3. | Renaissance Technologies Jim Simons | 1,152,270 | $1,463,383 | +114% | 0% |
| 4. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 1,145,214 | $1,454,422 | +9% | 0.08% |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 1,068,200 | $1,356,614 | -5% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.46 | 150,000 | $669,585.00 | 9,929,963 | 2023-10-02 | Filing | |
| $5.26 | 200,000 | $1,052,840.00 | 9,779,963 | 2023-09-07 | Filing | |
| $4.91 | 15,000 | $73,650.00 | 33,074 | 2023-08-30 | Filing | |
| $5.07 | 500,000 | $2,532,600.00 | 9,579,963 | 2023-02-14 | Filing | |
| $5.30 | 150,000 | $794,925.00 | 9,079,963 | 2023-01-19 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.56 | 423 | $1,082.88 | 9,532 | 2025-02-15 | Filing | |
| $18.22 | 3,165 | $57,666.30 | 0 | 2024-04-04 | Filing | |
| $17.74 | 5,351 | $94,926.74 | 3,165 | 2024-04-04 | Filing | |
| $16.38 | 232 | $3,800.16 | 8,516 | 2024-04-04 | Filing | |
| $15.51 | 147 | $2,279.97 | 8,748 | 2024-04-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,929,963 | $12,611,053 | 0.28% | |
| 2. | 4,913,128 | $6,239,673 | 0% | |
| 3. | 4,425,992 | $5,621,010 | 0% | |
| 4. | 3,250,248 | $4,127,815 | 0.02% | |
| 5. | 3,175,665 | $4,033,095 | 0.18% |
News See All
MacroGenics, Inc. (NASDAQ:MGNX) Q2 2024 Earnings Call Transcript
Operator: Good afternoon. We will begin the MacroGenics 2024 Third Quarter Corporate Progress and Financial Results Conference Call in just a moment.
MacroGenics, Inc. (NASDAQ:MGNX) Q1 2024 Earnings Call Transcript
Operator: Good afternoon. We will begin the MacroGenics 2024 First Quarter Corporate Progress and Financial Results Conference Call in just a moment.
MacroGenics, Inc. (NASDAQ:MGNX) Q4 2023 Earnings Call Transcript
Operator: Good afternoon. We will begin the MacroGenics 2023 Fourth Quarter Corporate Progress and Financial Results Conference Call in just a moment.
12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
In this article, we discuss 12 most undervalued biotech stocks to buy according to hedge funds.
MacroGenics, Inc. (NASDAQ:MGNX) Q3 2023 Earnings Call Transcript
Operator: Good afternoon. We will begin the MacroGenics 2023 Third Quarter Corporate Progress and Financial Results Conference Call in just a moment.
MacroGenics, Inc. (NASDAQ:MGNX) Q2 2023 Earnings Call Transcript
Operator: Good afternoon. We will begin the MacroGenics 2023 Second Quarter Corporate Progress and Financial Results Conference Call in just a moment.
MacroGenics, Inc. (NASDAQ:MGNX) Q1 2023 Earnings Call Transcript
Operator: Good afternoon. We will begin the MacroGenics 2023 First Quarter Corporate Progress and Financial Results Conference Call in just a moment.
MacroGenics, Inc. (NASDAQ:MGNX) Q4 2022 Earnings Call Transcript
Operator: Good afternoon. We will begin the MacroGenics 2022 Fourth Quarter Corporate Progress and Financial Results Conference Call in just a moment.
MacroGenics Inc (MGNX): Hedge Funds Taking Some Chips Off The Table
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios.